|
시장보고서
상품코드
2144556
유방암 액체 생검 검사 기기 시장(2026-2030년)Global Breast Cancer Liquid Biopsy Testing Devices Market 2026-2030 |
||||||
세계의 유방암 액체 생검 검사 기기 시장은 2025년부터 2030년까지 12억 2,686만 7,500달러 증가하고, 예측 기간 동안 CAGR은 24.3%가 될 전망입니다.
세계 유방암 액체 생검 검사 기기 시장에 관한 본 보고서에서는 종합적인 분석, 시장 규모 및 전망, 동향, 성장 요인, 과제는 물론, 약 25개 업체를 대상으로 한 업체 분석을 제공합니다.
본 보고서는 현재의 시장 상황, 최신 동향 및 촉진요인, 그리고 전반적인 시장 환경에 대한 최신 분석을 제공합니다. 이 시장의 성장은 동반진단의 적응증 확대, 유방암 유병률 증가, AI 및 디지털 중합효소 연쇄 반응(PCR) 기술의 통합에 의해 주도되고 있습니다.
본 조사는 업계 주요 관계자로부터 얻은 정보를 포함한 1차 및 2차 정보를 객관적으로 결합하여 수행되었습니다. 본 보고서에는 주요 기업 분석 외에도 종합적인 시장 규모 데이터, 지역별 분석을 포함한 세분화 시장, 그리고 벤더 현황이 수록되어 있습니다. 보고서에는 과거 데이터 및 예측 데이터가 포함되어 있습니다.
| 시장 범위 | |
|---|---|
| 기준 연도 | 2025년 |
| 종료 연도 | 2030년 |
| 조사 기간 | 2026-2030년 |
| 성장 모멘텀 | 가속 |
| 2026년 전년 대비 | 23.7% |
| CAGR | 24.3% |
| 증가액 | 12억 2,686만 7,500달러 |
본 조사에서는 임상 현장에서의 도입을 촉진하는 동반진단이 향후 수년간 전 세계 유방암 액체 생검 검사 기기 시장의 성장을 견인할 주요 요인 중 하나라고 규명하고 있습니다. 또한, 멀티오믹스 분야의 기술 발전과 미세잔류병변(MRD)에 대한 관심이 높아지고 있는 점도 시장에서 상당한 수요를 창출할 것으로 예상됩니다.
목차
제1장 주요 요약
제2장 Technavio 분석
제3장 시장 구도
제4장 시장 규모
제5장 시장 규모 실적
제6장 정성 분석
제7장 Five Forces 분석
제8장 시장 세분화 : 유형별
제9장 시장 세분화 : 최종사용자별
제10장 시장 세분화 : 소재별
제11장 고객 상황
제12장 지역별 상황
제13장 촉진요인, 과제, 기회
제14장 경쟁 구도
제15장 경쟁 분석
제16장 부록
KSMThe global breast cancer liquid biopsy testing devices market is forecasted to grow by USD 1226867.5 thousand during 2025-2030, accelerating at a CAGR of 24.3% during the forecast period. The report on the global breast cancer liquid biopsy testing devices market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by expansion of companion diagnostic indications, rising prevalence of breast malignancies, technological integration of ai and digital polymerase chain reaction.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 23.7% |
| CAGR | 24.3% |
| Incremental Value | $1226867.5 thousand |
Technavio's global breast cancer liquid biopsy testing devices market is segmented as below:
By Type
- CTCs and CNAs
- Extracellular vesicles
By End-User
- Hospitals and clinics
- Diagnostic laboratories
- Academic and research institutes
By Material
- Assay kits and reagents
- Instruments and diagnostic platforms
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the companion diagnostics driving clinical adoption as one of the prime reasons driving the global breast cancer liquid biopsy testing devices market growth during the next few years. Also, technological advancements in multiomics and shift toward minimal residual disease will lead to sizable demand in the market.
The report on the global breast cancer liquid biopsy testing devices market covers the following areas:
- Global breast cancer liquid biopsy testing devices market sizing
- Global breast cancer liquid biopsy testing devices market forecast
- Global breast cancer liquid biopsy testing devices market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global breast cancer liquid biopsy testing devices market vendors that include Agilent Technologies Inc., Bio Rad Laboratories Inc., Bio Techne Corp., Burning Rock Biotech Ltd., Caris Life Sciences Inc., Cellbox Solutions GmbH, Exact Sciences Corp., F. Hoffmann La Roche Ltd., Genecast Biotechnology Co. Ltd., Guardant Health Inc., Illumina Inc., Laboratory Holdings Inc., Menarini Silicon Biosystems, Myriad Genetics Inc., Natera Inc., NeoGenomics Laboratories Inc., Predicine Inc., QIAGEN N.V., SeekIn Inc., Sysmex Corp., Thermo Fisher Scientific Inc., Veracyte Inc.. Also, the global breast cancer liquid biopsy testing devices market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Market Segmentation by Material
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Breast Cancer Liquid Biopsy Testing Devices Market 2020 - 2024
- Historic Market Size - Data Table on Global Breast Cancer Liquid Biopsy Testing Devices Market 2020 - 2024 ($ thousand)
- 5.2 Type segment analysis 2020 - 2024
- Historic Market Size - Type Segment 2020 - 2024 ($ thousand)
- 5.3 End-user segment analysis 2020 - 2024
- Historic Market Size - End-user Segment 2020 - 2024 ($ thousand)
- 5.4 Material segment analysis 2020 - 2024
- Historic Market Size - Material Segment 2020 - 2024 ($ thousand)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ thousand)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ thousand)
6 Qualitative Analysis
- 6.1 Impact of AI on Global Breast Cancer Liquid Biopsy Testing Devices Market
- 6.2 Impact of geopolitical conflicts on Global Breast Cancer Liquid Biopsy Testing Devices Market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Type
- 8.1 Market segments
- 8.2 Comparison by Type
- 8.3 CTCs and CNAs - Market size and forecast 2025-2030
- 8.4 Extracellular vesicles - Market size and forecast 2025-2030
- 8.5 Market opportunity by Type
- Market opportunity by Type ($ thousand)
9 Market Segmentation by End-user
- 9.1 Market segments
- 9.2 Comparison by End-user
- 9.3 Hospitals and clinics - Market size and forecast 2025-2030
- 9.4 Diagnostic laboratories - Market size and forecast 2025-2030
- 9.5 Academic and research institutes - Market size and forecast 2025-2030
- 9.6 Market opportunity by End-user
- Market opportunity by End-user ($ thousand)
10 Market Segmentation by Material
- 10.1 Market segments
- 10.2 Comparison by Material
- 10.3 Assay kits and reagents - Market size and forecast 2025-2030
- 10.4 Instruments and diagnostic platforms - Market size and forecast 2025-2030
- 10.5 Market opportunity by Material
- Market opportunity by Material ($ thousand)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 India - Market size and forecast 2025-2030
- 12.5.3 Japan - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Indonesia - Market size and forecast 2025-2030
- 12.5.6 Thailand - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.3 UAE - Market size and forecast 2025-2030
- 12.6.4 Turkey - Market size and forecast 2025-2030
- 12.6.5 Argentina - Market size and forecast 2025-2030
- 12.6.6 Colombia - Market size and forecast 2025-2030
- 12.6.7 South Africa - Market size and forecast 2025-2030
- 12.6.8 Israel - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ thousand)
- Data Tables on Market opportunity by geography ($ thousand)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Expansion of companion diagnostic indications
- Rising prevalence of breast malignancies
- Technological integration of AI and digital polymerase chain reaction
- 13.2 Market challenges
- Analytical sensitivity and biomarker scarcity
- Complex regulatory pathways and reimbursement
- High infrastructure and operational costs
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Companion diagnostics driving clinical adoption
- Technological advancements in multiomics
- Shift toward minimal residual disease
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Agilent Technologies Inc.
- Agilent Technologies Inc. - Overview
- Agilent Technologies Inc. - Business segments
- Agilent Technologies Inc. - Key news
- Agilent Technologies Inc. - Key offerings
- Agilent Technologies Inc. - Segment focus
- SWOT
- 15.5 Bio Rad Laboratories Inc.
- Bio Rad Laboratories Inc. - Overview
- Bio Rad Laboratories Inc. - Business segments
- Bio Rad Laboratories Inc. - Key news
- Bio Rad Laboratories Inc. - Key offerings
- Bio Rad Laboratories Inc. - Segment focus
- SWOT
- 15.6 Bio Techne Corp.
- Bio Techne Corp. - Overview
- Bio Techne Corp. - Business segments
- Bio Techne Corp. - Key news
- Bio Techne Corp. - Key offerings
- Bio Techne Corp. - Segment focus
- SWOT
- 15.7 Burning Rock Biotech Ltd.
- Burning Rock Biotech Ltd. - Overview
- Burning Rock Biotech Ltd. - Business segments
- Burning Rock Biotech Ltd. - Key offerings
- Burning Rock Biotech Ltd. - Segment focus
- SWOT
- 15.8 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.9 Genecast Biotechnology Co. Ltd.
- Genecast Biotechnology Co. Ltd. - Overview
- Genecast Biotechnology Co. Ltd. - Product / Service
- Genecast Biotechnology Co. Ltd. - Key offerings
- SWOT
- 15.10 Guardant Health Inc.
- Guardant Health Inc. - Overview
- Guardant Health Inc. - Product / Service
- Guardant Health Inc. - Key offerings
- SWOT
- 15.11 Illumina Inc.
- Illumina Inc. - Overview
- Illumina Inc. - Business segments
- Illumina Inc. - Key news
- Illumina Inc. - Key offerings
- Illumina Inc. - Segment focus
- SWOT
- 15.12 Laboratory Holdings Inc.
- Laboratory Holdings Inc. - Overview
- Laboratory Holdings Inc. - Business segments
- Laboratory Holdings Inc. - Key offerings
- Laboratory Holdings Inc. - Segment focus
- SWOT
- 15.13 Menarini Silicon Biosystems
- Menarini Silicon Biosystems - Overview
- Menarini Silicon Biosystems - Product / Service
- Menarini Silicon Biosystems - Key offerings
- SWOT
- 15.14 Myriad Genetics Inc.
- Myriad Genetics Inc. - Overview
- Myriad Genetics Inc. - Product / Service
- Myriad Genetics Inc. - Key offerings
- SWOT
- 15.15 QIAGEN N.V.
- QIAGEN N.V. - Overview
- QIAGEN N.V. - Product / Service
- QIAGEN N.V. - Key offerings
- SWOT
- 15.16 Sysmex Corp.
- Sysmex Corp. - Overview
- Sysmex Corp. - Business segments
- Sysmex Corp. - Key offerings
- Sysmex Corp. - Segment focus
- SWOT
- 15.17 Thermo Fisher Scientific Inc.
- Thermo Fisher Scientific Inc. - Overview
- Thermo Fisher Scientific Inc. - Business segments
- Thermo Fisher Scientific Inc. - Key news
- Thermo Fisher Scientific Inc. - Key offerings
- Thermo Fisher Scientific Inc. - Segment focus
- SWOT
- 15.18 Veracyte Inc.
- Veracyte Inc. - Overview
- Veracyte Inc. - Product / Service
- Veracyte Inc. - Key offerings
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
